Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
- 26 October 2006
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 20 (14), 2576-2578
- https://doi.org/10.1096/fj.06-6463fje
Abstract
A number of hypotheses regarding how anti-Abeta antibodies alter amyloid deposition have been postulated, yet there is no consensus as to how Abeta immunotherapy works. We have examined the in vivo binding properties, pharmacokinetics, brain penetrance, and alterations in Abeta levels after a single peripheral dose of anti-Abeta antibodies to both wild-type (WT) and young non-Abeta depositing APP and BRI-Abeta42 mice. The rapid rise in plasma Abeta observed after antibody (Ab) administration is attributable to prolongation of the half-life of Abeta bound to the Ab. Only a miniscule fraction of Ab enters the brain, and despite dramatic increases in plasma Abeta, we find no evidence that total brain Abeta levels are significantly altered. Surprisingly, cerebral spinal fluid Abeta levels transiently rise, and when Ab:Abeta complex is directly injected into the lateral ventricles of mice, it is rapidly cleared from the brain into the plasma where it remains stable. When viewed in context of daily turnover of Abeta, these data provide a framework to evaluate proposed mechanisms of Abeta attenuation mediated by peripheral administration of an anti-Abeta monoclonal antibody (mAb) effective in passive immunization paradigm. Such quantitative data suggest that the mAbs are either indirectly enhancing clearance of Abeta or targeting a low abundance aggregation intermediate.Keywords
Funding Information
- Mayo Foundation for Medical Education and Research
This publication has 56 references indexed in Scilit:
- Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivoNature Medicine, 2006
- The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brainNeurobiology of Disease, 2005
- Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodiesAnnals of Neurology, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- Systemic Catabolism of Alzheimer's Aβ40 and Aβ42Online Journal of Public Health Informatics, 2004
- Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease modelNature Neuroscience, 2002
- Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in PlasmaBiochemical and Biophysical Research Communications, 2000
- Binding of Gelsolin, a Secretory Protein, to Amyloid β-ProteinBiochemical and Biophysical Research Communications, 1999
- Intravascular infusions of soluble β-amyloid compromise the blood–brain barrier, activate CNS glial cells and induce peripheral hemorrhageBrain Research, 1999
- The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL/6 mice with a half‐life of 6–8 daysEuropean Journal of Immunology, 1986